Emerging research suggest Retatrutide , a dual agonist targeting both the gut-brain axis and another hormone, may offer a significant development for body management . Preliminary clinical tests have shown substantial losses in abdominal tissue, potentially surpassing other body composition medications . However , more study is required to fully de